Articles by Chul Soo Ha, MD
ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma
ByKaren M. Winkfield, MD, PhD,Ranjana H. Advani, MD,Leslie K. Ballas, MD,Bouthaina S. Dabaja, MD,Sughosh Dhakal, MD,Christopher R. Flowers, MD, MS,Chul Soo Ha, MD,Bradford S. Hoppe, MD, MPH,David B. Mansur, MD,Nancy P. Mendenhall, MD,Monika L. Metzger, MD,John P. Plastaras, MD, PhD,Kenneth B. Roberts, MD,Ronald Shapiro, MD,Sonali M. Smith, MD,Stephanie A. Terezakis, MD,Anas Younes, MD,Louis S. Constine, MD By combining the most recent medical literature and expert opinion, this revised guideline can aid clinicians in the complex decision-making associated with the management of recurrent Hodgkin lymphoma.
ACR Appropriateness Criteria® Localized Nodal Indolent Lymphoma
ByBradford S. Hoppe, MD, MPH,David C. Hodgson, MD,Ranjana H. Advani, MD,Bouthaina S. Dabaja, MD,Christopher R. Flowers, MD, MS,Chul Soo Ha, MD,Monika L. Metzger, MD,John P. Plastaras, MD, PhD,Kenneth B. Roberts, MD,Ronald Shapiro, MD,Stephanie A. Terezakis, MD,Karen M. Winkfield, MD, PhD,Anas Younes, MD,Louis S. Constine, MD The present guidelines review epidemiology, pathology, presentation, workup, staging, prognostic factors, and treatment options for patients with localized nodal indolent lymphoma, with an emphasis on radiation guidelines, including radiation dose, field design, and radiation techniques.
If systemic treatment is effective enough to reliably control not only microscopic but also bulky disease, there will be little role for radiotherapy. And if systemic treatment cannot even reliably control microscopic disease, let alone macroscopic disease, there will be little role for radiotherapy, either. However, there are patients who fall into neither of these categories, and in them radiotherapy may well have a role.
